EGFR and non-small cell lung carcinoma: A first-in-man phase I study of the oral small molecule STAT3 inhibitor OPB-51602 resulted in partial response in 5% of patients with EGFR-mutant NSCLC and resistance to EGFR tyrosine kinase inhibitors (NCT01184807) [222].